View Cart  

FDA Studying Inclusion of Risk/Benefit Information in DTC Advertising

The FDA needs more time to make a decision about whether risk/benefit information should be added to prescription drug promotional labeling or advertising, the agency said in a recent report to Congress.

To View This Article:


Subscribe To The Executive Briefing Series

Buy This Article Now

Add this article to your cart for $40.00